Impaired semen quality is frequent in Western countries and is the main reason or contributing reason in up to 50% of cases of couple infertility. Male factor infertility is mainly determined by examination of semen samples according to the World Health Organization's 2010 guidelines. AMH has both autocrine and paracrine properties through a direct effect via the AMH type II receptor and is therefore thought to be involved in spermatogenesis. We aimed to study the association between the serum concentration of AMH and semen quality in a cross-sectional study including 970 young Danish men from the general population. All participants provided a semen sample, had a blood sample drawn, underwent a physical examination, and answered a questionnaire including information on lifestyle and medical history. Serum concentrations of reproductive hormones [AMH, luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone (T), calculated free T, oestradiol (E2) and inhibin B] and semen parameters (semen volume, sperm concentration, and percentages of motile and morphologically normal spermatozoa) were determined. We found no association between serum AMH and semen quality, except for a significant (p = 0.011) trend for lower percentage of normal morphology with higher AMH. AMH quartile was positively associated with serum inhibin B (p < 0.001), inhibin B/FSH ratio (p < 0.001) and T/E2 ratio (0.016), and negatively associated with FSH (p = 0.004), LH (p = 0.005) and E2 (p = 0.028). There was no association between AMH quartile and T, calculated free T or total T/LH ratio. In conclusion, serum AMH is not useful as a marker of semen quality, and semen analysis using WHO criteria is still the golden standard in the evaluation of the infertile man.
INTRODUCTION
Impaired semen quality is frequent in Western countries and is the main reason or contributing reason in up to 50% of cases of couple infertility (Inhorn & Patrizio, 2015) . Male factor infertility is mainly determined by examination of semen samples according to the World Health Organization's 2010 guidelines (World Health Organization, 2010) . Inhibin B is the best serum marker of semen quality together with follicle-stimulating hormone (FSH) (Jensen et al., 1997; Kumanov et al., 2006) , although the association between sperm counts and inhibin B is strongest at low levels of both (Jorgensen et al., 2010) . Additionally, anti-M€ ullerian hormone (AMH) has been suggested as a direct biomarker of Sertoli cell function and indirect marker of spermatogenesis (Fenichel et al., 1999; Fujisawa et al., 2002; Mostafa et al., 2007) .
The clinical and diagnostic value of measuring serum AMH concentrations in paediatric endocrinology is well established.
AMH is a testis-specific marker in newborn infants with ambiguous genitalia or non-palpable gonads and is therefore a clinically useful marker in the evaluation of children with disorders of sexual differentiation (DSD) (Josso et al., 1993; Lee et al., 1997) . Furthermore, in contrast to testosterone (T), luteinizing hormone (LH) and FSH, both AMH and inhibin B are measurable without prior stimulation test all through infancy and childhood and AMH and inhibin B are therefore important biochemical markers of the pituitary-gonadal function in boys (Grinspon et al., 2014) . In contrast, the exact physiological role of postnatal AMH and the clinical applicability of AMH measurements in adult men remain to be determined.
AMH has both autocrine and paracrine properties through a direct effect via the AMH type II receptor (Teixeira et al., 2001) and is therefore thought to be involved in spermatogenesis. However, the existing data are limited, and the results conflicting with overlap between fertile and infertile men. The aim of this study was therefore to evaluate whether serum AMH and semen quality are associated in a large cohort of healthy men not selected due to semen quality or fertility status.
MATERIALS AND METHODS

Study population
979 healthy young men from the general population of Denmark were randomly selected among participants in an ongoing study on semen quality (Jorgensen et al., 2002) . Only men recruited during the years 2004 to 2007 were included in this study. In Denmark, all young men except those suffering from severe chronic diseases are required to attend a compulsory medical examination to determine their fitness for military service. Therefore, these men may be considered representative of the general population of young men. Details from this study have previously been described (Jorgensen et al., 2002) . The participation rate among invited men was approximately 30%. Nine participants were excluded due to self-reported use of anabolic steroids (n = 5) or the combination of a LH concentration <0.75, a low sex hormone-binding globulin (SHBG) and unmeasurable serum T (n = 4) indicative of anabolic steroid abuse, leaving a total of 970 healthy young men for analysis for this study.
All participants underwent a physical examination including the assessment of testis size by palpation and ultrasound, provided a semen sample and had a blood sample drawn. The time of semen and blood sampling was recorded. All semen and blood samples were collected between 8.40 AM and 11.50 AM. All participants fulfilled a questionnaire including the information on lifestyle and medical history.
Hormone analyses
Blood samples were drawn from an antecubital vein, and the serum was stored at À20°C until analysis. AMH was measured by a sensitive immunoassay [Immunotech, Beckman Coulter Ltd., Marseilles, France (A16507)] with a detection limit of 2 pmol/L. The intra-assay coefficients of variation (CVs) were <7.8, 5.4, and 6.4% at 13, 123 and 231 pmol/L, respectively. The interassay CVs were <11.6, 10.9, and 9.1% at 19, 99 and 209 pmol/L, respectively, as previously described (Aksglaede et al., 2010) . SHBG, FSH and LH were measured by time-resolved fluoroimmunoassay (Autodelfia, Wallac, Turku, Finland) with detection limits of 0.23 nmol/L, 0.05 IU/L and 0.05 IU/L, respectively. Intra-and interassay coefficients of variation (CVs) were 6% in all three assays. Testosterone was measured with the DPC Coat-A-Count radioimmunoassay kit (Diagnostic Products, Los Angeles, CA, USA). The detection limit was 0.23 nmol/L, and the intra-and interassay CVs were 10%, respectively. Oestradiol (E2) was measured by radioimmunoassay (Pantex, Santa Monica, CA, USA). The detection limit was 18 pmol/L; the intra-and interassay CVs were 8% and 13%, respectively. Inhibin B was determined by a double-antibody enzyme-immunometric assay using kit material from the inhibin B genII assay (Beckman Coulter, Brea, CA, USA), together with an in-house recombinant inhibin B standard. Intra-and interassay CVs for inhibin B were 15 and 18%, respectively. The limit of detection was 3 pg/mL. Free testosterone (cFT) was calculated using the equation of Vermeulen (Vermeulen et al., 1999) from total T and SHBG, assuming a fixed albumin level of 43.8 g/L.
Semen analysis
All participants provided a semen sample by masturbation in a room adjacent to the semen laboratory. The ejaculation abstinence period was recorded, and the semen sample was analysed as described according to Jørgensen et al. (Jorgensen et al., 2012) and thus in accordance with the current World Health Organization's 2010 guidelines (World Health Organization, 2010) .
Briefly, semen volume was estimated by weighing the collection tube with the semen sample and subtracting the predetermined weight of the empty tube, assuming that 1 mL semen = 1 g. For sperm motility assessment, 10 lL of wellmixed semen was placed on a clean glass slide kept at 37°C and covered with a 22 9 22 mm coverslip. The preparation was placed on the heated stage of a microscope at 37°C and immediately examined at 9400 magnification. The spermatozoa were classified as progressively motile, locally motile or immotile. For the assessment of the sperm concentration, the samples were diluted in a solution of 0.6 mol/L NaHCO 3 and 0.4% (v/v) formaldehyde in distilled water. The sperm concentration was subsequently assessed using a B€ urker-T€ urk haemocytometer (Paul Marienfeld GmbH & Co. KG, Lauda-K€ onigshofen, Germany). Only spermatozoa with tails were counted. Smears were prepared for morphological evaluation, Papanicolaou stained and finally assessed according to 'strict criteria' (Jorgensen et al., 2012) .
Analysis of sperm concentration and motility was carried out in duplicates on fresh samples by one examiner per sample. Sperm morphology was assessed later in batches by two technicians. Motility was analysed within 60 min for 78% of samples, and 95% of samples were analysed within 90 min. All samples were analysed within 120 min.
Statistics
Physical and biochemical characteristics as well as semen parameters are provided as unadjusted median (and 5-95% percentiles) or frequencies. AMH quartiles were calculated.
For models of association between AMH and semen and reproductive hormone variables, multiple linear regression analyses were performed. Dependent variables were ln transformed (all reproductive hormone concentrations and progressively motile), cubic root transformed (semen volume, sperm concentration, total sperm count) or square root transformed (morphologically normal) to achieve normality of distribution of residuals. The fit of the regression model was evaluated for each analysis by testing the residuals to assure normal distribution. Linear trend analyses were performed by including the individual AMH concentrations rather than the categories in regression models. To test for effects of the 10% highest and 10% lowest concentrations of AMH, all analyses were furthermore performed including AMH percentile in the regression models.
Covariates evaluated in the statistical model included factors possibly associated with semen parameters and levels of reproductive hormones. In models of associations between serum AMH and semen variables, none of the tested covariates substantially changed the p-value or effect estimate. However, abstinence time was included in regression models for all semen quality variables, and additionally, smoking (current) and BMI were included in regression models for semen volume, sperm concentration, total sperm count and morphologically normal. BMI, smoking (current), time of blood sampling and testosterone (except when T and cFT were the outcome variables) were included as covariates in regression models for all reproductive hormones to facilitate interpretation of results.
Although the majority of included men were Danish, some were of non-Danish origin (other European countries, Africa, Asia, South America, America and Middle Eastern countries). Subanalyses of results including only ethnic Danish men did not change any estimates (data not shown), and the reported results are therefore based on analyses of the whole study population.
Reference curves for Figure 1 were estimated using the generalized additive models for location, scale and shape (GAMLSS) (Rigby & Stasinopoulos, 2005) . The method employs an agedependent (using cubic splines) Box-Cox power transformation, which transforms the data to follow a Gaussian distribution for each age. Prediction intervals are then calculated and backtransformed.
A p-value< 0.05 was considered statistically significant. Statistical analysis was conducted using the IBM statistics SPSS version 22.0 (IBM, Armonk, NY, USA).
Ethical aspects
The study was conducted according to the Declaration of Helsinki and was approved by the Danish National Committee on Biomedical Research Ethics (reference no. H-KF-289428). Participants signed informed consent before participation.
RESULTS
Basic characteristics including stratification according to quartiles of serum AMH of the entire group of 970 men included in this study are shown in Table 1 . Median age of the men was 19.0 (18.4-21.3) years. Men in the higher AMH quartiles had significantly lower weight (p = 0.002), BMI (p = 0.004) and larger testicles (p < 0.0001). There was no difference in AMH concentrations between smokers and non-smokers, men with or without a history of sexually transmitted disease, or between men drinking more or <21 units of alcohol per week. Approximately 11% of men had taken some medicine at some time during the 3 months prior to participating in the study. For most of them, it was either antibiotics, painkillers or asthma-/allergy-related medicine on an occasional basis. Taking medicine did not have any effect on the AMH concentration. The majority of the men 288 Andrology, 2018, 6, 286-292
were of Danish origin (88.1%). There was no difference in AMH concentrations between Danish men and men of foreign origin (Table 1) .
AMH and spermatogenesis-related parameters
Reproductive hormones and semen parameters for the whole study population and stratified according to AMH quartile are shown in Table 2 . The levels of the semen variables did not differ between men from the four AMH groups except for sperm morphology, where a significant (p = 0.011) trend for lower percentage of normal morphology with higher AMH was found.
When stratifying the data into the 10% lowest, 10% highest and the 80% in between of AMH concentration (data not shown), we found a significant difference in the sperm concentration (p = 0.005), total sperm count (p = 0.033) and morphology (p = 0.04), but no difference in semen volume (p = 0.33) or progressively motile (p = 0.55). There was a significant (p = 0.036) trend for a higher percentage of morphologically normal spermatozoa in men within the 10% lowest AMH concentration category. Sperm concentration and total sperm count were lowest in men within the 10% lowest AMH concentration category and highest in the 80% in between.
There was a significant positive association between AMH quartile and the concentration of inhibin B (p < 0.001) and inhibin B/FSH ratio (p < 0.001) and inverse between AMH quartile and FSH (p = 0.004). Figure 1 illustrates the associations between sperm concentration and total sperm count and serum concentrations of inhibin B (positive), FSH (negative), inhibin B/FSH ratio (positive) and AMH (none), respectively, with the corresponding reference lines (mean, AE1 SD and AE2 SD).
AMH and Leydig cell parameters
There was a significant negative association between AMH quartile and LH (p = 0.005) and E2 (p = 0.028) (Table 2) , a positive association between AMH quartile and T/E2 ratio (0.016), but no association between AMH quartile and T (p = 0.17), cFT (p = 0.69), SHBG (p = 0.054) or T/LH ratio (p = 0.10).
DISCUSSION
In this large cross-sectional study of 970 healthy young men from the general population, we found no association between the serum concentration of AMH and semen quality, except for a significant inverse association between serum AMH and the percentage of morphologically normal spermatozoa. The data were both analysed with stratification on 
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AMH quartile and AMH percentile to ensure that there was no effect of the highest or lowest concentrations of AMH. The serum concentration of AMH was positively associated with the serum concentration of inhibin B and inhibin B/FSH ratio, and negatively associated with the serum concentration of FSH. These results indicate a positive association between AMH and Sertoli cell function and suggest that serum AMH may be an endocrinological marker of spermatogenesis, although this was not directly reflected in the semen quality. Furthermore, we found no association between serum AMH concentration and the serum concentration of T, but a significant negative association between serum AMH and LH and a positive between AMH and T/E2. Altogether, our findings indicate that there is no association between serum AMH and spermatogenesis, although our data suggest an association with morphology.
Other studies have been performed to elucidate the role of both serum and seminal concentrations of AMH on spermatogenesis. Some authors have found a correlation between the serum concentrations of AMH and semen quality (Al-Qahtani et al., 2005; Appasamy et al., 2007; Goulis et al., 2008; Tsametis et al., 2011; Kucera et al., 2016) , whereas others have not found any association (Isikoglu et al., 2006; Tuttelmann et al., 2009; ElHalawaty et al., 2011; Goulis et al., 2011; Andersen et al., 2016) . The data on seminal concentrations of AMH are more convincing than the results of the studies on serum concentrations of AMH (Fenichel et al., 1999; Fujisawa et al., 2002; Mostafa et al., 2007) , although another study did not confirm an association between seminal concentrations of AMH and spermatogenesis (Al-Qahtani et al., 2005) . Additionally, four studies found no value of seminal AMH concentration in the prediction of successful testicular sperm extraction (TESE) in patients with nonobstructive azoospermia (Mostafa et al., 2007; Duvilla et al., 2008; Goulis et al., 2009; Mitchell et al., 2010) .
Most recently, Andersen et al. found a significant positive association between total AMH (pmol/ejaculate) in seminal plasma and sperm concentration, total sperm count, total sperm motility and progressive sperm motility, but no association between seminal AMH and normal morphology (Andersen et al., 2016) . However, some men presenting with low or undetectable seminal concentration of AMH had sperm concentrations above 15 million/mL, supporting previous findings (Fenichel et al., 1999) indicating that AMH may not be predictive of sperm quality at least at low concentrations of AMH. In that study, a total of 126 men were included of which 94 were from the general population and 32 were recruited from couples with female factor infertility.
We found a positive association between AMH and T/E2 ratio, which may indicate that AMH downregulates aromatase activity. However, the reduction in T/E2 ratio is not reflected in other hormones (e.g. LH), and the biological effect of this reduction therefore seems minimal.
AMH is exclusively secreted by Sertoli cells in men and by granulosa cells of small follicles in females (Lee & Donahoe, 1993) . In men, AMH is expressed by immature Sertoli cells from approximately gestational week 8 (Josso et al., 1993; Rajpert-De Meyts et al., 1999) and is essential for a normal sexual development by triggering the regression of the M€ ullerian ducts in the male foetus (Lee & Donahoe, 1993) . In healthy boys, the serum concentration of AMH increases significantly during the first post-natal months during the so-called 'mini-puberty' followed by a decline to a stable level during childhood (Aksglaede et al., 2010) . During childhood, the immature Sertoli cells differentiate and start to express androgen receptors (Chemes et al., 2008) and thereby become responsive to increasing concentrations of intratesticular T resulting in a concomitant decline in AMH secretion with advancing pubertal development and in adulthood. The secretion of AMH is inhibited by androgens (Rey et al., 1994) and stimulated by FSH (Young et al., 2005) . After puberty, AMH is secreted bidirectionally by the Sertoli cells: basally to the circulation and apically into the lumen of the seminiferous tubules (Fenichel et al., 1999) . AMH is mainly secreted by the apical pole of the Sertoli cell, and the concentration of AMH may be up to 10 times higher in seminal fluid as compared with serum (Fenichel et al., 1999) .
The higher concentrations of AMH in semen as compared to serum may be an indication of a possible role in spermatogenesis as well as sperm motility, although this is not reflected by the existing studies. The existing data indicate that the concentration of AMH in seminal plasma may be superior to the serum concentration of AMH as a marker of spermatogenesis. However, if semen sampling is necessary, the advantage of having an indirect marker of semen quality disappears and direct determination of the semen quality should be performed.
Our observed inverse association between serum AMH and percentage of morphologically normal spermatozoa has to our knowledge not been reported before, but an inverse association between both morphology and motility and the concentration of AMH in seminal plasma was found in 1996 in the study by Fallat et al., (1998) . These authors speculate that the increased seminal concentration of AMH may be associated with a primary defect causing reduced morphology and motility and that the observed increase in AMH therefore was not reflecting the semen quality itself. However, in the study by Fallat et al., the seminal concentration of AMH was significantly lower in donors with normal semen parameters as compared with subfertile patients and is therefore not in accordance with the results of the more recent studies. The same authors studied the effect of recombinant human AMH [formerly and in the original paper termed MIS (M€ ullerian inhibiting substance)] on fresh and cryopreserved spermatozoa and found a significantly higher motility and viability of fresh spermatozoa after 5-and 22-h incubation . Coincubation with anti-AMH eliminated the effects of AMH.
We have not been able to find a biological explanation for the inverse association between serum AMH and morphology. The cross-sectional nature of the study does not allow us to draw conclusions on this association, and further studies are needed to elucidate whether this association is direct or caused by a second factor associated with AMH.
Serum AMH is significantly higher in untreated men with congenital or acquired hypogonadotropic hypogonadism as compared with healthy post-pubertal men (Young et al., 1999) . This phenomenon is a result of the absent downregulation of AMH production due to the impaired testosterone production in these men and is in line with the findings in boys with defects in androgen synthesis or with an androgen insensitivity syndrome (Rey et al., 1994) . In contrast, we and others have previously shown that serum AMH concentrations are within the normal 290 Andrology, 2018, 6, 286-292 reference in infants and children with Klinefelter syndrome (47, XXY), but significantly reduced after pubertal onset in these patients (Lahlou et al., 2004; Bastida et al., 2007; Aksglaede et al., 2011) . We hypothesize that this decline is a result of the progressive hyalinization of seminiferous tubules in relation to puberty, rather than caused by disrupted regulatory mechanisms at the level of the pituitary-gonadal axis.
This study has several strengths. The study is large, with a high participation rate of approximately 30%, which is higher than participation rates in other population-based studies of semen quality. The participants are young and healthy, and the vast majority (93%) had no prior knowledge of their own fertility potential. Thus, it was a group of men from the general population (Jorgensen et al., 2012) representing a wide range of semen quality levels and AMH levels. Therefore, we consider it unlikely that selection bias explain our results. Furthermore, all analyses of semen parameters were performed blinded, and the same technicians assessed all morphology slides. However, our study was cross-sectional, and we only obtained one semen sample from each man, and our study therefore did not take intra-individual variability in semen parameters into account. Regarding the circadian rhythm in hormone production, all blood samples were taken in the mornings, and we adjusted sampling times to 8.00 AM. A limitation of this study is the measurement of AMH by the IOT assay (Immunotech by Beckman Coulter, Marseilles, France). However, it has been shown that the older assays correlate well with the new AMH Generation II assay (Gen II by Beckman Coulter, Inc., Breas, CA, USA) (Lindhardt et al., 2013) . The major limitation of our study is the lack of data on seminal concentration of AMH for comparison.
In conclusion, the serum concentration of AMH is not associated with sperm concentration, total sperm count or sperm motility in healthy men, but may be associated with the percentage of morphologically normal spermatozoa. AMH is therefore not useful as a marker of semen quality, and semen analysis using WHO criteria is still the golden standard in the evaluation of the infertile man. AMH is a marker of Sertoli cell differentiation and function with a potential role in the evaluation of men suspected of hypogonadotropic hypogonadism, anorchia or 47, XXY. However, further studies are needed to evaluate the clinical applicability of AMH in the endocrine evaluation of such patients.
